The use of faecal microbiota transplantation (FMT) as treatment for recurrent Clostridium difficile infection (CDI) has increased rapidly over the past few years. In this review, we highlight clinical studies of FMT for treatment of recurrent CDI and discuss the safety, standardization and future of this treatment option. The major risk factor for CDI is prior antibiotic use, which results in an altered state of the gut microbiota characterized by decreased microbial diversity. This altered gut microbiota increases the patient's susceptibility to CDI. In patients with recurrent CDI, the microbiota remains in a state with decreased diversity, and FMT from a healthy individual restores the gut microbiota and subsequently colonization resistance against the pathogen.
INTRODUCTION
In recent years, a new focus has been put on Clostridium difficile due to the emergence of hyperendemic strains that have led to outbreaks around the world and an increasing incidence of disease [1] . C. difficile is an anaerobic, spore-forming, Grampositive bacilli and is now the leading cause of hospital-acquired infections, surpassing methicillin-resistant Staphylococcus aureus (MRSA) [2] . In hospitals, C. difficile infection (CDI) is the number one cause of pseudomembranous colitis and significant nosocomial diarrhoea cases [3] . CDI is responsible for significant morbidity, mortality and increased economic burden in hospitalized patients, approaching 5 billion dollars annually [4,5 & ]. Risk for the development of CDI is associated with the use of broad spectrum antibiotic therapy as well as increasing patient age and hospitalization [6] . As many as 50% of people become colonized with antimicrobial therapy, which has led to a search for alternative treatments for refractory disease. One old but recently popular alternative therapy is faecal microbiota transplantation (FMT) in which the faecal microbiota from a healthy host is transferred to a patient with recurrent CDI in order to restore the microbiota to a resistant state against CDI [12] .
Establishment of a healthy gut microbiota is critical in order to resolve the symptoms of recurrent CDI. The gut microbiota provides multiple benefits to the host, one of which is to mediate colonization resistance against gut pathogens [13, 14] . The first modern use of FMT was described in 1958 as a treatment for pseudomembranous enterocolitis [15] . However, accounts of FMT date all the way back to fourth century China where it was used to treat severe diarrhoea [16] . An altered gut microbiota after antibiotic treatment can be restored to a community that is resistant to CDI via FMT. The use of FMT for the treatment of recurrent CDI has been shown to be a well tolerated and effective treatment when primary treatment options have failed. As the recurrence rate of CDI increased over the last decade, so has the interest in FMT for the treatment of recurrent CDI. The previous year resulted in multiple comprehensive reviews on FMT describing use for treatment of a variety of diseases [17 & ], the preparation and screening of faeces [18] , and outcomes in clinical use for treatment of recurrent CDI [19] . The purpose of this review is to highlight recent advances in the use of FMT for recurrent CDI, describe potential concerns from this treatment and to identify areas of future research.
RANDOMIZED, CONTROLLED STUDY RECENTLY PERFORMED
There have been several systematic reviews of the literature examining the success rate of FMT in the treatment of recurrent CDI [20 & ,21] . In addition, a long-term follow-up of patients who received FMT to treat recurrent CDI showed that the primary cure rate was 91% [22 && ]. However, in order to confirm the efficacy of this treatment, a randomized, controlled study was needed. Such a study was recently reported by van Nood et al. [23 && ] who assessed the success rate of FMT via a nasoduodenal tube. The study showed that resolution of recurrent CDI was more effective with FMT than with vancomycin treatment alone. The authors found that 81% of patients receiving FMT had resolution of recurrent CDI symptoms without relapse for 10 weeks, compared with 31% receiving vancomycin treatment [23 && ]. The success rate of CDI resolution is similar to the systematic review and meta-analysis of uncontrolled cases showing CDI resolution 92% of the time [20 
PROGRESS HAS BEEN MADE IN THE STANDARDIZATION OF FAECAL MICROBIOTA TRANSPLANTATION PREPARATION
In previous studies, faeces for transplantation has generally been donated by a family member of the patient. This material is then screened for enteric pathogens (such as C. difficile, Helicobacter pylori, Giardia and Cryptosporidium) and viruses (such as hepatitis and HIV). The faeces is then diluted (in saline, milk or water) and homogenized with a blender. Particulates are then filtered out and the faeces is ready for transplantation. The procedure of obtaining, screening and processing the faeces sample for FMT, dosage and number of treatments has varied [20 & ,21] ; however, it should be noted that even with this variation, the FMT still resulted in greater than 80% resolution of recurrent CDI [21] .
The use of individual donors for FMT has prompted some investigators to determine whether prescreened and stored faeces could be used for treatment of recurrent CDI. A recent study by Hamilton et al. [24 && ] described a protocol for the processing and freezing of donor faeces that now allows for universal donors and more accessibility to donor faeces. Importantly, this standardization protocol did not lose any apparent efficacy when used for treatment of recurrent CDI even though the donor faeces was frozen prior to FMT. The standardization process is important in several ways. First, it showed that a standardized, volunteer faeces donation programme was accepted for use by the patients. A recent survey assessing patient perceptions for
KEY POINTS
Recent work has shown the efficacy of using FMT to treat recurrent CDI.
There is a standardized method to prepare and freeze donor faeces that is ready to use when needed.
Progress has been made in developing a defined bacterial community for the treatment of recurrent CDI.
More work needs to be done to understand how specific members of the gut microbiota can restore colonization resistance against C. difficile.
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FMT to treat ulcerative colitis found that almost 50% of patients preferred donor faeces from a family member as opposed to whomever their doctor recommended [25] . Using donor faeces from a family member is the most common approach to obtaining donor faeces and this study showed that patients were willing to use a standardized, volunteer faeces donation programme. Second, it shows a protocol to cryopreserve the faeces that is effective in treating recurrent CDI. This allows the faeces to be processed in advance, stored and can be shipped to other hospitals when needed. This will greatly increase the availability of donor faeces leading to more accessibility for this treatment. Finally, using universal donors and creating multiple preps is a cost-effective means of FMT due to a decreased cost in screening on the universal donor faeces as opposed to having to screen each individual donor [26] .
BACTERIOTHERAPY TO TREAT RECURRENT CLOSTRIDIUM DIFFICILE INFECTION
For many people, the thought of being treated with the use of another individual's faeces is not an attractive option. This 'ick' factor turns people away from this treatment [27 & ]. Although treatment with FMT is becoming more widespread, there is interest in identifying the species of bacteria in faeces that mediate colonization resistance against C. difficile. Once specific members have been identified, they can be isolated and used to create a defined bacterial community that can be administered to patients instead of faeces. Bacteriotherapy is an attractive treatment option, as a defined bacterial community would be a very reproducible treatment that is more accessible than faeces and free of any known pathogenic bacteria or viruses. This area of research has been of great interest to the field and recent work is summarized below.
Going from faeces that contains thousands of different species of bacteria to a simple defined bacterial community presents a huge challenge. Which bacteria are the ones that mediate colonization resistance against C. difficile? Previous work has shown that certain phyla of bacteria correlate with CDI. In a murine model of infection, mice with CDI showed a decrease in the abundance of Firmicutes (specifically Lachnospiraceae) and an increase in Proteobacteria [28] . The inverse was seen when the gut microbiota was analysed following treatment of patients with recurrent CDI with FMT. In multiple studies, patients showed an increase in the abundance of Firmicutes (specifically Lachnospiraceae) and a decrease in Proteobacteria [23 && ,29]. From these correlations, we can start to identify species of bacteria that increase post-FMT and examine their role as antagonists to CDI. Single species have been isolated that decrease the clinical signs of CDI in a germ-free mouse model of infection [30, 31] . Recent work by Lawley et al. [32 & ] showed that as few as six species of bacteria can restore colonization resistance during a CDI using a murine model of infection. In addition, work by Petrof et al. [33 && ] identified 33 bacterial isolates that when given to patients by colonoscopy resolved recurrent CDI.
The creation of a defined bacterial community for bacteriotherapy is exciting, however still in its early stages. Work by Petrof et al. [33 && ] followed two patients with recurrent CDI and although both showed no signs of recurrent CDI 6 months after treatment, it is difficult to draw conclusions for the use of this treatment on a larger patient population. The authors note that they are continuing to develop defined bacterial communities for bacteriotherapy in order to treat a larger patient population. Additional studies are then needed to obtain a defined community of bacteria that is sufficient to treat recurrent CDI to the same efficacy as FMT.
COULD A FAECAL MICROBIOTA TRANSPLANTATION HAVE LONG-TERM UNINTENDED CONSEQUENCES?
Although FMT may effectively treat recurrent CDI, the long-term consequences of this treatment have yet to be determined. As our knowledge of the gut microbiota increases, so does our understanding that the gut microbiota plays a role in several disease states. We know that the gut microbiota is associated with many gastrointestinal diseases, including obesity [34] , inflammatory bowel disease [35] and colon cancer [36] . In addition, links have been made with correlating an altered gut microbiota to neurologic [37] and autoimmune disorders [38] . These studies provide only correlations between the microbiota and disease; we still do not understand the mechanism behind these disease states and the role that the microbiota specifically plays. We do not know whether it is a specific bacterium or a community of bacteria that cause the disease. As much is still unknown, we cannot screen out potentially harmful bacteria the same way we can screen out C. difficile from faeces used to treat recurrent CDI. Therefore, any potential long-term consequences of this treatment are currently unknown until we can fully characterize the role of the microbiota in disease.
The use of FMT for treatment of recurrent CDI has been shown to be well tolerated in the short term. Systematic reviews and meta-analysis done on the use of FMT for recurrent CDI showed no adverse effects from the treatment [20 & ,21] . The recent study by van Nood et al. [23 && ] found only minor side effects to the treatment, including cramping and belching, with all symptoms resolved within 3 h after treatment. However, a recent study [39] described a patient who developed ulcerative colitis after FMT was used in the treatment of recurrent CDI. This patient had a history of quiescent ulcerative colitis for the previous 20 years and symptoms reemerged after FMT. It is possible the patient's genetic susceptibility to ulcerative colitis could have played a role in disease reemergence and the authors speculate that introducing a new microbiota may have caused an immune response leading to the flare up of ulcerative colitis. This case suggests that care needs to be taken when using this treatment on patients with previous gastrointestinal disorders. Although disease development from FMT is very small compared with the successful resolution of recurrent CDI, it is important to understand any potential unintended consequences from this treatment. More research is needed to understand the variability that people exhibit in their microbiota and how FMT could potentially lead to disease in order to help minimize these unintended consequences.
FAECAL MICROBIOTA TRANSPLANTATION IS NOW AN INVESTIGATIONAL NEW DRUG WITH SELECTIVE ENFORCEMENT
The recent progress in the standardization of FMT is an important advancement for the field. However, some have argued that use of this treatment is expanding too rapidly without proper review and testing of the procedure. Recently, the U.S. Food and Drug Administration (FDA) has designated FMT as an investigational new drug (IND), meaning that physicians must apply to a federal board and obtain permission to perform the procedure. This is because the faecal microbiota for transplantation is being used to treat disease; therefore, it meets the legal definition of a drug and biological product [40] . However, physicians have argued that applying IND requirements could restrict the use of FMT for the treatment of recurrent CDI. Recently, the FDA has acknowledged these concerns and is willing to use enforcement discretion for the use of FMT to treat recurrent CDI [41] . This effectively no longer requires a physician to get IND approval from the FDA prior to treatment. However, the discretion of the enforcement for IND requirements will be given to physicians who obtain informed consent from the patient stating that FMT for the treatment of recurrent CDI is an investigation drug and explains any potential risks for this treatment.
With this new decision from the FDA comes an urgent need for clinical trials using a standardized protocol for obtaining and processing of the faeces. The FDA has stated that they are ready to work with researchers who are interested in conducting clinical trials [41] . However, prior to clinical studies, the field needs to define exactly what is the drug (is it a gut microbial community or a protocol to process faeces?), what it is approved for (how many recurrent CDI infections does a patient need before treatment?), the duration and route of administration. Once these issues are addressed, standardized clinical trials can move forward with the hope of not only increasing access to this treatment but also developing a well tolerated and reliable drug that decreases any potential long-term consequences from this treatment.
CONCLUSION
The use of FMT for the treatment of recurrent CDI is an important treatment option after multiple rounds of antibiotics are unable to resolve recurrent CDI. Recent work has shown this to be a well tolerated and effective treatment for recurrent CDI that has the potential to be scaled up for widespread distribution and use [23
]. However, we do not understand mechanistically how FMT resolves recurrent CDI, we simply know that it works. Without understanding the mechanism of protection, we run the risk of potential long-term consequences by transferring potentially harmful bacteria that can alter the gut microbiota to promote a disease state. Although FMT for the treatment of recurrent CDI is well tolerated in the short term, more research is needed to identify any long-term consequences of this treatment.
The idea of using faeces for a gut microbiota (as opposed to using a defined bacterial community) is as close to a 'one-size fits all' approach we have right now to treat every patient. However, we know that there is a large variability in the gut microbiota from person to person [42] . In addition, we know that probiotics/bacteriotherapy require a specific gut microbiota in order to grow and thrive once the bacteriotherapy is stopped [43] . Using a defined bacterial community for bacteriotherapy might not reach the success rates FMT has for resolution of recurrent CDI. This is an exciting area of research wherein work is ongoing to address these questions. With a better understanding of colonization resistance mechanisms against CDI, we can better develop a more targeted bacteriotherapy that will hopefully treat a broad range of patients.
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